Synthesis of exemestane labelled with 13C

Steroids

Volumn 73, Issue 7, 2008, Pages 760-764

  Fontana, Erminia ^a   Pignatti, Alberto ^a   Giribone, Danilo ^a   Di Salle, Enrico ^b  

^a NERVIANO MEDICAL SCIENCES   (Italy)

^b PFIZER INC   (United States)

Author keywords

13C; Aromatase inhibitor; Exemestane; Internal standard; Labelling; LC MS

Indexed keywords

AROMATASE INHIBITOR; CARBON 13; EXEMESTANE; TESTOSTERONE;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING;

ANDROSTADIENES; CARBON ISOTOPES; ISOTOPE LABELING; TESTOSTERONE;

EID: 43849112972     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2008.02.010     Document Type: Article

References (15)

1. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
2. Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 18 (2000) 1399-1411
3. Goss P., and von Eichel L. Summary of aromatase inhibitor trials: the past and future. J Steroid Biochem Mol Biol 106 (2007) 40-48
4. Breda M., Pianezzola E., and Strolin Benedetti M. Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 620 (1993) 225-231
5. Allievi C., Zugnoni P., Strolin Benedetti M., and Dostert P. Determination of plasma levels of exemestane (FCE 24304) a new irreversible aromatase inhibitor, using liquid chromatography-thermospray mass spectrometry. J Mass Spectrom 30 (1995) 693-697
6. Persiani S., Broutin F., Cicioni P., Stefanini P., and Strolin Benedetti M. Determination of the new aromatase inhibitor exemestane in biological fluids by automated high-performance liquid chromatography followed by radioimmunoassay. Eur J Pharm Sci 4 (1996) 331-340
7. 2 steroids. Steroids 39 (1982) 279-290
8. 13C] estradiol. Steroids 44 (1984) 283-292
9. 5] 19-nortestosterone. Labelled Comp Radiopharm 36 (1995) 745-754
10. 13C in the steroid A ring. Part 2. Tetrahedron 56 (2000) 9967-9974
11. Cenacchi V., Barattè S., Cicioni P., Frigerio E., Long J., and James C. J Pharm Biomed Anal 22 (2000) 451-460
12. Mauras N., Lima J., Patel D., Rini A., di Salle E., Kwok A., et al. Pharmacokinetics and dose finding of a potent aromatase inhibitor, Aromasin (exemestane), in young males. J Clin Endocrinol Metab 88 (2003) 5951-5956
13. Rivera E., Valero V., Francis D., Asnis A.G., Schaaf L.J., Duncan B., et al. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 10 (2004) 1943-1948
14. Hutson P.R., Love R.R., Havighurst T.C., Rogers E., and Cleary J.F. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Clin Cancer Res 11 (2005) 8722-8727
15. Traiana T.A., Poggesi I., Robson M., Asnis A., Duncan B.A., Heerdt A., et al. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat (2007) [Epub ahead of print]